Skip to content

11th World Congress on Alternatives and Animal Use in the Life Sciences 2021

SEAC scientists presented many aspects of collaborative research at the 11th World Congress on Alternatives and Animal Use in the Life Sciences which was held virtually between 23rd August – 2nd September 2021.

Unilever Oral Presentations

  • Next Generation Risk Assessment for consumer safety: What do we need from validation? - Dr Carl Westmoreland
  • Decision making in non-animal cosmetic safety assessment – Dr Paul Russell
  • An industry perspective on strategies for integrating new approach methodologies for Next Generation Risk Assessment: coumarin as a case study – Dr Maria Baltazar
  • In silico approaches to link adverse outcomes to molecular initiating events through AOPs – Dr Tim Allen
  • AFSA module on Integrating in vitro data to establish a Margin of Exposure - Sophie Cable
  • Integration of ReproTracker® into a next generation risk assessment (NGRA) approach - Dr Iris Muller
  • Scientific workshop on Non-animal approaches for Chemical Safety in China: Current Progress and Outlook - Dr Carl Westmoreland
  • Evaluation of a new approach methodology toolbox for the next generation risk assessment of systemic toxicity - Sophie Cable

Unilever Sponsored Sessions

  • Accelerating use of new science and technology for Chemical Safety Assessment – chaired by Dr Gavin Maxwell
  • Accelerating use of Computational Science for Chemical Safety Assessment – chaired by Dr Catherine Willett
  • Industry and Federal Agencies working together for a common (non-animal) good: The Unilever and EPA Collaborative Research and Development Agreements (CRADA) – chaired by Dr Russell Thomas & Prof. Paul Carmichael
  • Assessing non-specific cellular stress responses for Chemical Safety Assessment – chaired by Dr Paul Walker & Dr Paul Russell
  • Cross Species Extrapolation: Opportunities for Chemical Safety Assessment – chaired by Dr Carl Westmoreland
  • A collaborative approach to develop new NAMs for Chemical Safety Assessment – chaired by Dr Iris Muller
  • Optimising in vitro methods through removal of serum components – chaired by Dr Carol Treasure & Dr Sarah Hatherell

Unilever Poster Presentations

  • P22: Workshop on the Implementation of Next Generation Risk Assessment (NGRA) for Systemic Toxicity – Mabel Cotter
  • P61: Next generation risk assessment of human exposure to anti-androgens using newly defined comparator compound values – Tessa van Tongeren
  • P99: Next Generation Risk Assessment approach for Inhalation: Polymer case studies – Dr Maria Baltazar
  • P100: Identifying and Characterising Stress Pathways of Concern for Consumer Safety in Next Generation Risk Assessments – Dr Maria Baltazar
  • P106: A Next Generation Risk Assessment Case Study for Coumarin in Hypothetical Cosmetic Products – Sophie Cable
  • P148: Practical application of in silico approaches in Next Generation Risk Assessment for consumer products – Dr Steve Gutsell
  • P149: Framework for Physiologically-Based Kinetics (PBK) modelling in the Next Generation Risk Assessment (NGRA) of Consumer Goods – Dr Tom Moxon
  • P151: Next Generation Risk Assessment (NGRA) for Skin Allergy: Use of Coumarin in Cosmetic Products, Ab Initio Case Study – Georgia Reynolds
  • P262: Towards the Development of Animal Product-Free in vitro Systems for NGRA of Consumer Goods (PDF 265.6 KB) – Dr Sarah Hatherell
  • P438: Non-Animal Safety Assessment Case Study of Phenoxyethanol in Cosmetics – Dr Matthew Dent (presented on behalf of Cosmetics Europe LRSS)
  • P486: Building confidence in using new approach methodologies for consumer-based risk assessment: challenges and future perspectives – Dr Alistair Middleton
  • P579: An in vitro panel for cosmetic chemical systemic toxicity safety testing – Dr Predrag Kukic (presented on behalf of Cosmetics Europe LRSS)
Back to top